{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:27:55Z","timestamp":1761863275669,"version":"build-2065373602"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.clcc.2013.12.005","type":"journal-article","created":{"date-parts":[[2014,1,4]],"date-time":"2014-01-04T10:15:37Z","timestamp":1388830537000},"page":"81-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["A Phase II Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Biliary Tract Cancers"],"prefix":"10.1016","volume":"13","author":[{"given":"Crystal S.","family":"Denlinger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal J.","family":"Meropol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy L.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul F.","family":"Engstrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis M.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan D.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Katherine","family":"Alpaugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven J.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2013.12.005_bib1","first-page":"10","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clcc.2013.12.005_bib2","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1056\/NEJM199910283411807","article-title":"Biliary tract cancers","volume":"341","author":"de Groen","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2013.12.005_bib3","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/1097-0142(19920915)70:6<1493::AID-CNCR2820700608>3.0.CO;2-U","article-title":"Carcinoma of the gallbladder. Histologic types, stage of disease, grade, and survival rates","volume":"70","author":"Henson","year":"1992","journal-title":"Cancer"},{"key":"10.1016\/j.clcc.2013.12.005_bib4","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1002\/1097-0142(19920915)70:6<1498::AID-CNCR2820700609>3.0.CO;2-C","article-title":"Carcinoma of the extrahepatic bile ducts. Histologic types, stage of disease, grade, and survival rates","volume":"70","author":"Henson","year":"1992","journal-title":"Cancer"},{"key":"10.1016\/j.clcc.2013.12.005_bib5","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/1097-0142(19840915)54:6<965::AID-CNCR2820540603>3.0.CO;2-X","article-title":"Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer","volume":"54","author":"Falkson","year":"1984","journal-title":"Cancer"},{"key":"10.1016\/j.clcc.2013.12.005_bib6","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1023\/A:1008241008379","article-title":"Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin","volume":"9","author":"Ducreux","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2013.12.005_bib7","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1200\/JCO.1996.14.8.2311","article-title":"Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer","volume":"14","author":"Patt","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2013.12.005_bib8","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00280-005-0095-3","article-title":"Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer","volume":"57","author":"Okusaka","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clcc.2013.12.005_bib9","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1023\/A:1012543223020","article-title":"A\u00a0phase II study of gemcitabine in gallbladder carcinoma","volume":"12","author":"Gallardo","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2013.12.005_bib10","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0959-8049(01)00214-3","article-title":"First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study","volume":"37","author":"Papakostas","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2013.12.005_bib11","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1023\/A:1011135014895","article-title":"A\u00a0phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma","volume":"12","author":"Sanz-Altamira","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2013.12.005_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1634\/theoncologist.7-1-9","article-title":"Development of the proteasome inhibitor PS-341","volume":"7","author":"Adams","year":"2002","journal-title":"Oncologist"},{"key":"10.1016\/j.clcc.2013.12.005_bib13","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO.2005.11.030","article-title":"Proteasome inhibition as a novel therapeutic target in human cancer","volume":"23","author":"Rajkumar","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2013.12.005_bib14","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1053\/he.2000.6127","article-title":"p27Kip1 expression in normal epithelia, precancerous lesions, and carcinomas of the gallbladder: Association with cancer progression and prognosis","volume":"31","author":"Hui","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.clcc.2013.12.005_bib15","first-page":"3994","article-title":"Low p27 expression is an independent predictor of survival for patients with either hilar or peripheral intrahepatic cholangiocarcinoma","volume":"7","author":"Fiorentino","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2013.12.005_bib16","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1053\/jhep.2001.24028","article-title":"The role of p27kip1 protein expression on the biological behavior of intrahepatic cholangiocarcinoma","volume":"33","author":"Taguchi","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.clcc.2013.12.005_bib17","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1002\/hep.510300506","article-title":"Decreased p27kip1 expression and cyclin D1\u00a0overexpression, alone or in combination, influence recurrence and survival of patients with resectable extrahepatic bile duct carcinoma","volume":"30","author":"Hui","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.clcc.2013.12.005_bib18","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/hep.510260413","article-title":"Bcl-2 is overexpressed and alters the threshold for apoptosis in a cholangiocarcinoma cell line","volume":"26","author":"Harnois","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.clcc.2013.12.005_bib19","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1023\/A:1005412626515","article-title":"Mutations of p53 tumor suppressor gene, apoptosis, and proliferation in intrahepatic cholangiocellular carcinoma of the liver","volume":"45","author":"Tannapfel","year":"2000","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.clcc.2013.12.005_bib20","first-page":"998","article-title":"Expression of nuclear factor kappa B in hepatitis C virus core gene transfected cholangiocarcinoma cells","volume":"115","author":"Xoapfang","year":"2002","journal-title":"Chin Med J"},{"key":"10.1016\/j.clcc.2013.12.005_bib21","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3748\/wjg.v13.i6.851","article-title":"Proteasome inhibition induces endoplasmic reticulum dysfunction and cell death of human cholangiocarcinoma cells","volume":"13","author":"Ustundag","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clcc.2013.12.005_bib22","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.3748\/wjg.v13.i33.4458","article-title":"Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells","volume":"13","author":"Baradari","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clcc.2013.12.005_bib23","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s00432-013-1473-6","article-title":"Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma","volume":"139","author":"Vaeteewoottacharn","year":"2013","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clcc.2013.12.005_bib24","first-page":"2638","article-title":"The proteasome inhibitor PS-341 in cancer therapy","volume":"5","author":"Teicher","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2013.12.005_bib25","unstructured":"Millennium Pharmaceuticals. Velcade Package Insert. 2011; http:\/\/www.velcade.com\/. Accessed May 25,\u00a02011."},{"key":"10.1016\/j.clcc.2013.12.005_bib26","first-page":"2505","article-title":"A\u00a0phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies","volume":"8","author":"Aghajanian","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2013.12.005_bib27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/cncr.20753","article-title":"Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma","volume":"103","author":"Alberts","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.clcc.2013.12.005_bib28","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/annonc\/mdh351","article-title":"Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study","volume":"15","author":"Andr\u00e9","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2013.12.005_bib29","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1002\/cncr.21591","article-title":"Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced\/metastatic biliary tract carcinoma","volume":"104","author":"Cho","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.clcc.2013.12.005_bib30","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1200\/JCO.2005.51.008","article-title":"Combining gemcitabine and capecitabine in\u00a0patients with advanced biliary cancer: a phase II trial","volume":"23","author":"Knox","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2013.12.005_bib31","doi-asserted-by":"crossref","first-page":"vii68","DOI":"10.1093\/annonc\/mdl955","article-title":"Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers","volume":"17","author":"Verderame","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2013.12.005_bib32","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria\u00a0for Adverse Events version 3.0. 2006. Available at: http:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcaev3.pdf. Accessed February 10, 2012."},{"key":"10.1016\/j.clcc.2013.12.005_bib33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clcc.2013.12.005_bib34","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/00000421-200008000-00023","article-title":"Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas","volume":"23","author":"Choi","year":"2000","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clcc.2013.12.005_bib35","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1200\/JCO.2001.19.20.4089","article-title":"Treatment of inoperable and\/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study","volume":"19","author":"Gebbia","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2013.12.005_bib36","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1023\/A:1008352123009","article-title":"Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer","volume":"12","author":"Penz","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2013.12.005_bib37","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/01.sla.0000251366.62632.d3","article-title":"Cholangiocarcinoma: thirty-one year experience with 564 patients at a single institution","volume":"245","author":"DeOliveira","year":"2007","journal-title":"Ann Surg"},{"key":"10.1016\/j.clcc.2013.12.005_bib38","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0002-9610(01)00628-6","article-title":"Predictive factors for long-term survival in patients with intrahepatic cholangiocarinoma","volume":"181","author":"Isa","year":"2001","journal-title":"Am J Surg"},{"key":"10.1016\/j.clcc.2013.12.005_bib39","unstructured":"NCCN Practice Guidelines in Oncology. Hepatobiliary Cancers, v.1.2013. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp. Accessed: January 14,\u00a02014."},{"key":"10.1016\/j.clcc.2013.12.005_bib40","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2013.12.005_bib41","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/sj.bjc.6603648","article-title":"Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials","volume":"96","author":"Eckel","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2013.12.005_bib42","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0360-3016(01)01446-8","article-title":"Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-\u03baB","volume":"50","author":"Russo","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clcc.2013.12.005_bib43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1006\/jsre.2001.6194","article-title":"Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome","volume":"100","author":"Bold","year":"2001","journal-title":"J\u00a0Surg Res"},{"key":"10.1016\/j.clcc.2013.12.005_bib44","first-page":"3535","article-title":"Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341","volume":"61","author":"Cusack","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.clcc.2013.12.005_bib45","first-page":"6316","article-title":"The proteasome as a target for cancer therapy","volume":"9","author":"Voorhees","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2013.12.005_bib46","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial","volume":"28","author":"Harousseau","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2013.12.005_bib47","first-page":"40","article-title":"HOVON-65\/GMMG-HD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM)","volume":"116","author":"Sonneveld","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.clcc.2013.12.005_bib48","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2013.12.005_bib49","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clcc.2013.12.005_bib50","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002813001321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002813001321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:02:04Z","timestamp":1761519724000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002813001321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S1533002813001321"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2013.12.005","relation":{},"ISSN":["1533-0028"],"issn-type":[{"type":"print","value":"1533-0028"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase II Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Biliary Tract Cancers","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2013.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}